<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Mammary Gland Biol Neoplasia</journal-id>
      <journal-title>Journal of Mammary Gland Biology and Neoplasia</journal-title>
      <issn pub-type="ppub">1083-3021</issn>
      <issn pub-type="epub">1573-7039</issn>
      <publisher>
        <publisher-name>Kluwer Academic Publishers-Plenum Publishers</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17286208</article-id>
      <article-id pub-id-type="pmc">1820839</article-id>
      <article-id pub-id-type="publisher-id">9040</article-id>
      <article-id pub-id-type="doi">10.1007/s10911-007-9040-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Extracellular Proteolysis in Transgenic Mouse Models of Breast Cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Almholt</surname>
            <given-names>Kasper</given-names>
          </name>
          <address>
            <phone>+45-3545-5750</phone>
            <fax>+45-3538-5450</fax>
            <email>kasper@finsenlab.dk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Green</surname>
            <given-names>Kirsty Anne</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Juncker-Jensen</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nielsen</surname>
            <given-names>Boye Schnack</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lund</surname>
            <given-names>Leif R&#xF8;ge</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>R&#xF8;mer</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Finsen Laboratory, Rigshospitalet 3735, Copenhagen BioCenter, Ole Maal&#xF8;es Vej 5, DK-2200 Copenhagen, Denmark </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>2</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2007</year>
      </pub-date>
      <volume>12</volume>
      <issue>1</issue>
      <fpage>83</fpage>
      <lpage>97</lpage>
      <permissions>
        <copyright-statement>&#xA9; Springer Science+Business Media, LLC 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Growth and invasion of breast cancer require extracellular proteolysis in order to physically restructure the tissue microenvironment of the mammary gland. This pathological tissue remodeling process depends on a collaboration of epithelial and stromal cells. In fact, the majority of extracellular proteases are provided by stromal cells rather than cancer cells. This distinct expression pattern is seen in human breast cancers and also in transgenic mouse models of breast cancer. The similar expression patterns suggest that transgenic mouse models are ideally suited to study the role of extracellular proteases in cancer progression. Here we give a status report on protease intervention studies in transgenic models. These studies demonstrate that proteases are involved in all stages of breast cancer progression from carcinogenesis to metastasis. Transgenic models are now beginning to provide vital mechanistic insight that will allow us to combat breast cancer invasion and metastasis with new protease-targeted drugs.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Plasminogen</kwd>
        <kwd>Urokinase uPA</kwd>
        <kwd>uPAR</kwd>
        <kwd>Fibrinolysis</kwd>
        <kwd>Matrix metalloprotease MMP</kwd>
        <kwd>DCIS</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media, LLC 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Breast cancer progression is accompanied by increased expression of proteases that are capable of degrading the extracellular matrix (ECM) leading to cancer cell invasion and eventually to dissemination of cancer cells to other organs. The proteolytic capability of breast cancers is reminiscent of the inherent proteolytic capability of the healthy mammary gland. Extracellular proteases are necessary for the dynamic tissue remodeling that takes place during normal mammary gland development and pregnancy cycling (reviewed in [<xref ref-type="bibr" rid="CR1">1</xref>]). During development, the invasive phenotype of terminal end buds is associated with a controlled proteolytic digestion of ECM in the fat pad, and side branching of the newly formed ducts requires a focal degradation of basement membrane. The proliferative response of the epithelium during pregnancy and lactation is accompanied by limited proteolytic activity. In contrast, the involution of the lactating gland to a resting gland after weaning restructures the entire gland and requires extensive degradation of ECM and basement membranes. Extracellular proteases are thus more abundant during involution than at any other stage during development and the pregnancy cycle. The similarity between the proteolytic repertoire of the normal gland and the proteolytic capability of mammary cancers is best illustrated by the fact that the cellular expression patterns of individual proteolytic components are very alike, especially when comparing involution and cancer [<xref ref-type="bibr" rid="CR2">2</xref>]. In terms of extracellular proteolysis, breast cancer in many ways resembles a mammary gland in a state of continuous and uncontrolled tissue remodeling.</p>
    </sec>
    <sec id="Sec2">
      <title>Matrix Metalloproteases and Plasminogen Activators</title>
      <p>Two families of extracellular proteases have been extensively studied in relation to mammary gland morphogenesis and cancer. These are the matrix metalloproteases (MMPs) and the group of serine proteases that govern the activation of plasminogen (Plg). Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> illustrates the connected extracellular proteolytic network of the MMPs and the Plg activation system (PA system).
<fig id="Fig1"><label>Figure&#xA0;1</label><caption><p>The PA and MMP systems in the mouse. Plasmin and MMPs are two major sources of extracellular proteolysis. Plg is converted to the active protease plasmin by one of three Plg activators, uPA, tPA, and pKal. The generation of plasmin is enhanced by the binding of uPA to the cell surface receptor uPAR, and by the binding of tPA to coagulated fibrin or to cell surface proteins (annexin II [<xref ref-type="bibr" rid="CR86">86</xref>] and CKAP4 [<xref ref-type="bibr" rid="CR87">87</xref>]). The conversion of pro-uPA to active uPA may be initiated by several proteases, depending on the tissue in question. Additional pro-uPA is then activated by plasmin in a positive feed-back loop. The PA system is tightly controlled by several serine protease inhibitors (serpins); the primary and most specific inhibitors are the Plg activator inhibitor PAI-1 that targets uPA and tPA, and the plasmin inhibitor &#x3B1;<sub>2</sub>-antiplasmin (&#x3B1;<sub>2</sub>AP). Major substrates of plasmin include fibrin, fibronectin, laminin, and other ECM proteins, latent TGF-&#x3B2; and other growth factors, and pro-MMPs. The 22 different mouse MMPs are all extracellular, and are either soluble or membrane-anchored. Like the serine proteases of the PA system, the MMPs are also synthesized as inactive proforms that require proteolytic activation. Ten of the 22 pro-MMPs, including the membrane-anchored MMPs, have a furin cleavage site and may be activated by furin-like proprotein convertases before they are secreted. The remaining pro-MMPs are activated extracellularly, typically by plasmin or by other MMPs. The MMP system is counterbalanced by a group of four inhibitors, TIMPs, that have varying specificities for individual MMPs. In addition, the membrane-anchored MMP inhibitor RECK regulates a subgroup of MMPs including MMPs-2, -9, and -14 [<xref ref-type="bibr" rid="CR88">88</xref>]. An excess of plasmin or MMP activity may ultimately be cleared by&#xA0;&#x3B1;<sub>2</sub>-macroglobulin (&#x3B1;<sub>2</sub>M) which is a non-specific protease scavenger. The MMPs are collectively able to degrade any component of the ECM. Important substrates for the MMPs as a group include the native fibrillar collagens and all four major components of the basement membrane: collagen type IV, laminin, nidogen/entactin, and heparan sulfate proteoglycans.</p></caption><graphic position="anchor" xlink:href="10911_2007_9040_Fig1_HTML" id="MO1"/></fig></p>
      <p>The liver-derived proenzyme Plg is found in high concentration throughout the body. In contrast, expression of the specific urokinase- and tissue-type Plg activators (uPA and tPA) is induced locally and thus determines where and when Plg is converted to the active protease plasmin [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Plasmin, activated by uPA, is important for a number of tissue remodeling processes that, in addition to pregnancy cycling of the mammary gland [<xref ref-type="bibr" rid="CR5">5</xref>], include wound healing [<xref ref-type="bibr" rid="CR6">6</xref>] and embryo implantation [<xref ref-type="bibr" rid="CR7">7</xref>]. In contrast, tPA is acknowledged to be primarily involved in thrombolysis and neurobiology [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] but is also active during wound healing [<xref ref-type="bibr" rid="CR8">8</xref>]. A newly identified Plg activator, plasma kallikrein (pKal), is involved in adipocyte differentiation in the involuting mammary gland [<xref ref-type="bibr" rid="CR9">9</xref>] and in wound healing [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>The MMPs constitute a large family of 22 extracellular metalloproteinases in mice (24 in humans) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] (an updated list of human and mouse proteases is available at <ext-link ext-link-type="uri" xlink:href="http://web.uniovi.es/degradome/">http://web.uniovi.es/degradome/</ext-link>). MMPs are essential for a number of physiological tissue remodeling processes during ontogenesis and adult life, including mammary gland development [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], bone development [<xref ref-type="bibr" rid="CR14">14</xref>], wound healing [<xref ref-type="bibr" rid="CR15">15</xref>], and embryo implantation [<xref ref-type="bibr" rid="CR7">7</xref>]. During mammary gland development MMP-2 is involved in ductal elongation, and MMPs-2 and -3 are involved in ductal branching [<xref ref-type="bibr" rid="CR13">13</xref>]. MMP-3 is also rate limiting for adipocyte differentiation during post-lactational involution [<xref ref-type="bibr" rid="CR16">16</xref>]. The ductal tree is eventually fully formed in mice that are deficient in MMP-2, -3 or several other MMPs, indicating that the remaining MMPs are able to replace their activity in a functional overlap.</p>
      <p>Several members of the MMP and PA systems are involved in breast cancer progression. We will focus on the role played by these extracellular protease families during the various stages of breast cancer progression, from the initial hyperplastic lesion to disseminated disease, with particular emphasis on the insight gained from transgenic mouse models.</p>
    </sec>
    <sec id="Sec3">
      <title>Mouse Models of Breast Cancer</title>
      <p>The mouse mammary gland is ideally suited to study cancer progression for a number of reasons. First of all, there are many similarities between the human and mouse mammary glands (for detailed reviews see [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]). Human and mouse mammary glands contain the same epithelial cell types: the ductal epithelial cells, luminal (milk secreting) epithelial cells, and the myoepithelial cells. They also contain adipose tissue and stroma, although the composition of the stroma differs between the human and mouse glands. One of the few differences between the species is that the epithelium in the mouse gland is surrounded by adipose tissue and a relatively sparse stroma, whereas the human mammary epithelium is encompassed by a specialized fibroblastoid stroma and is not in direct contact with adipocytes. The epithelial structure in the mature nulliparous mouse gland is also much less developed compared to the human gland and consists only of a branching but otherwise naked ductal tree. In contrast, the mature ductal tree in non-pregnant women contains groups of acini at the end of terminal ducts, named terminal ductal lobular units (TDLU). The mouse epithelium develops similar lobuloalveolar structures transiently during the estrus cycle in certain mouse strains [<xref ref-type="bibr" rid="CR19">19</xref>] and always during early pregnancy, and in this way the resting human gland is structurally more similar to the pregnant mouse gland. In some transgenic breast cancer models, the earliest hyperplastic lesions may also resemble TDLU-like structures [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
      <p>A second ideal feature of the mouse mammary gland is that it is readily accessible for monitoring tumor growth and for other experimental procedures. This has lead to the development of numerous transplanted models, chemically induced models and transgenic models. We will limit our discussion to the transgenic and chemically induced models since there are inherent problems of transplanted models that may introduce bias. Depending on the study design, these obstacles can include: (1) a species barrier between proteolytic components supplied by the transplant and the host (as documented for human and mouse uPA and its receptor uPAR [<xref ref-type="bibr" rid="CR21">21</xref>]); and (2) a cellular inconsistency with respect to protease expression in the sense that the majority of proteolytic components are supplied by stromal cells in human breast cancers while epithelial-based cancer cell lines often express the very same proteolytic components [<xref ref-type="bibr" rid="CR22">22</xref>]. This is presumably due to genetic alterations that have occurred during in vitro culture. Furthermore, (3) when gene-deficient mice are used as hosts for syngeneic transplantation, it is possible that a tumor-suppressive phenotype in the protease-deficient host is due to an immune response directed at the protease-producing transplant.</p>
      <p>A third advantage of the mammary gland for cancer research is that there are more transgenic models of mammary cancer than for any other cancer form, primarily because relatively specific promoters are available for targeting oncogene expression to the mammary epithelium. The promoters most frequently used stem from the whey acidic protein (WAP) gene, and the mouse mammary tumor virus long terminal repeat (MMTV). The promoters are not equally active at all stages of mammary gland development and the pregnancy cycle [<xref ref-type="bibr" rid="CR23">23</xref>]. The MMTV promoter is active during puberty but is greatly enhanced during pregnancy. The WAP promoter is primarily active from mid pregnancy and during lactation. Accordingly, cancer progression is accelerated by pregnancies in most transgenic models and some models only develop tumors after a number of pregnancies.</p>
      <p>Finally, the tumor histopathology of several transgenic models is very similar to human breast cancers [<xref ref-type="bibr" rid="CR17">17</xref>]. The histopathology seen in a single mouse model is, however, relatively uniform and often characteristic of the inducing oncogene, and in this way no single model replicates the variability of tumor phenotypes seen among different breast cancer patients [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. This drawback is to be expected, considering the fact that transgenic models rely on a well-defined initiating oncogene in mice with a homogenous genetic background (inbred strains). In contrast, human breast cancers arise from combinations of multiple mutations in women with heterogenous genetic backgrounds. A notable similarity between mouse and human tumors is the development of a reactive stroma and the appearance of extracellular proteolysis in the tumor microenvironment. There are, however, also significant drawbacks to the use of transgenic models, such as the fact that they express oncogenes in the entire mammary epithelium (or at least a large part of it) often giving rise to multiple tumors and in some models a general hyperplasia of the entire gland. By contrast, human tumors derive from a single site, therefore resulting in a single tumor in the breast.</p>
      <p>A comprehensive list of transgenic breast cancer models is available at <ext-link ext-link-type="uri" xlink:href="http://emice.nci.nih.gov/">http://emice.nci.nih.gov/</ext-link> and has recently been reviewed [<xref ref-type="bibr" rid="CR23">23</xref>]. Here we will focus on models that have been studied in relation to extracellular proteolysis. Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> summarizes the studies that describe MMP or PA system intervention in transgenic and chemically induced breast cancer models. It is evident from Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> that the role of proteases has almost exclusively been studied in models, in which one of the four oncoproteins ErbB-2 (neu) [<xref ref-type="bibr" rid="CR25">25</xref>], Ras [<xref ref-type="bibr" rid="CR26">26</xref>], Wnt1 [<xref ref-type="bibr" rid="CR27">27</xref>], or the polyomavirus middle T antigen (PymT) [<xref ref-type="bibr" rid="CR28">28</xref>] are induced by the MMTV promoter. ErbB-2 is often overexpressed in human breast cancers. Ras and the downstream effector proteins of Wnt1 and PymT are also frequently activated in human breast cancer, although mutation/overexpression of Ras and Wnt1 are infrequent in breast cancer and there is no cellular counterpart of the PymT oncogene [<xref ref-type="bibr" rid="CR23">23</xref>]. In all four transgenic models, tumor incidence is 100% or at least approaches 100% depending on the time allowed for observation [<xref ref-type="bibr" rid="CR29">29</xref>&#x2013;<xref ref-type="bibr" rid="CR32">32</xref>]. Tumor incidence has only in a few cases [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] been affected in protease intervention studies (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Tumor onset in the ErbB-2, Ras, and Wnt1 models can be accelerated by multiple pregnancies [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] and mice used for experiments are frequently mated continuously, at least in the Ras and Wnt1 models [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The PymT model is exceptionally fast even in non-pregnant mice, where the average tumor latency is approximately 1.5&#xA0;months [<xref ref-type="bibr" rid="CR31">31</xref>] compared to 4&#x2013;7&#xA0;months for multiparous mice in the three other models [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In all four models the tumors metastasize primarily to the lungs although the models differ in aggressiveness. The PymT model is the most aggressive and the Wnt1 model the least aggressive [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. A notable exception to the use of transgenic models in protease studies is the chemically induced mammary tumors that are induced by orally administered 7,12-dimethylbenzanthracene (DMBA) with or without hormone supplementation [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. The DMBA model is primarily a carcinogenesis model, since the tumors generally do not progress to form metastases [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. 
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>PA system and MMP intervention studies in transgenic and chemically induced breast cancer models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Proteolytic intervention</th><th>Mouse br.ca. model</th><th colspan="7">Phenotypic effect on mammary neoplasia</th><th>Reference</th></tr><tr><th/><th/><th>tumor incidence</th><th>tumor onset</th><th>tumor growth rate</th><th>final tumor size</th><th>lung metastasis incidence</th><th>lung metastasis burden</th><th>comments and additional phenotypes</th><th/></tr></thead><tbody><tr><td colspan="10">Plg activation system</td></tr><tr><td>Plg null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194; (&#x2193; trend)</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2193;</td><td>&#x2193;</td><td>reduced metastasis in 129:BSw:FVB mixed strain but not in FVB mice</td><td>[<xref ref-type="bibr" rid="CR44">44</xref>] and unpublished data</td></tr><tr><td>uPA null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194;(&#x2193; trend)</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2193;</td><td>+ reduced lymph node metastasis</td><td>[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td>PAI-1 null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194; (&#x2191; trend)</td><td>tumor vascularization not affected</td><td>[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td>uPAR null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>no phenotype in the FVB strain</td><td>unpublished data</td></tr><tr><td colspan="10">MMP protease family</td></tr><tr><td colspan="10">&#xA0;MMP overexpression</td></tr><tr><td>MMTV-MMP-3 transgene</td><td>none</td><td>yes*</td><td/><td/><td/><td/><td/><td>*tumors develop in the CD1 mouse strain but not in mixed B6:DBA mice</td><td>[<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR61">61</xref>], see comment in [<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td>WAP-MMP-3 transgene</td><td>none</td><td>yes*</td><td/><td/><td/><td/><td/><td>*tumors develop in the CD1 mouse strain but not in FVB mice</td><td>[<xref ref-type="bibr" rid="CR62">62</xref>], see comment in [<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td>MMTV-MMP-7 transgene</td><td>none</td><td>no</td><td/><td/><td/><td/><td/><td>hyperplasia in multiparous mice but no tumors develop spontaneously</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>MMTV-MMP-14 transgene</td><td>none</td><td>yes</td><td/><td/><td/><td/><td/><td>tumors develop spontaneously</td><td>[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td>MMTV-MMP-3 transgene</td><td>DMBA gavage</td><td>&#x2193;</td><td>&#x2193;</td><td/><td/><td/><td/><td>opposite expectation</td><td>[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td>MMTV-MMP-3 transgene</td><td>DMBA gavage + MMTV-TGF&#x3B1;</td><td>&#x2194;</td><td>&#x2194;</td><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td>MMTV-MMP-7 transgene</td><td>MMTV-neu</td><td>&#x2191;</td><td>&#x2191;</td><td>&#x2194;</td><td/><td>&#x2194;</td><td/><td/><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>MMTV-MMP-7 transgene</td><td>ApcMin + ENU</td><td>&#x2194;</td><td/><td/><td/><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr><tr><td colspan="10">&#xA0;MMP inhibition</td></tr><tr><td>MMP inhibitor-treatment (galardin/GM6001)</td><td>MMTV-PymT</td><td/><td/><td/><td>&#x2193;</td><td>&#x2193;</td><td>&#x2193;</td><td/><td>unpublished data</td></tr><tr><td>MMP-2 null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2193;</td><td>&#x2193;</td><td/><td>Fingleton and Matrisian, pers. comm.</td></tr><tr><td>MMP-7 null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td/><td>Fingleton and Matrisian, pers. comm.</td></tr><tr><td>MMP-7 null</td><td>ApcMin + ENU</td><td>&#x2193;</td><td/><td/><td/><td/><td/><td>transient reduction in number of mammary tumors</td><td>[<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr><tr><td>MMP-9 null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2193;</td><td>&#x2193;</td><td>reduced metastasis in mixed B6:FVB mouse strain but not in FVB mice</td><td>Fingleton and Matrisian, pers. comm.</td></tr><tr><td>MMP-9 null</td><td>MMTV-neu</td><td/><td>&#x2191;</td><td/><td/><td/><td/><td/><td>(meeting report [<xref ref-type="bibr" rid="CR67">67</xref>])</td></tr><tr><td>MMP-11 null</td><td>MMTV-ras</td><td>&#x2194;</td><td>&#x2193;</td><td/><td>&#x2193;</td><td>&#x2191;</td><td/><td>bidirectional effect</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>MMP-11 null</td><td>DMBA gavage</td><td>&#x2193;</td><td/><td/><td>&#x2193;</td><td/><td/><td>ovarian and mammary carcinomas</td><td>[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td>MMP-13 null</td><td>MMTV-PymT</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td/><td>unpublished data</td></tr><tr><td>WAP-TIMP-1 transgene</td><td>WAP-MMP-3</td><td>&#x2193;</td><td/><td/><td/><td/><td/><td>reduced incidence of hyperplasias, no tumors develop</td><td>[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td>Albumin-TIMP-1 transgene</td><td>DMBA gavage + MPA</td><td>&#x2193;</td><td/><td/><td/><td/><td/><td>early hyperplasia not affected</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td>Albumin-TIMP-1 transgene</td><td>MMTV-PymT</td><td>&#x2194;</td><td/><td/><td>&#x2193;</td><td>&#x2193;</td><td>&#x2194;</td><td/><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td>MMTV-TIMP-1 transgene</td><td>DMBA gavage + MPA</td><td/><td/><td/><td>&#x2194;</td><td/><td/><td/><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td>MMTV-TIMP-1 transgene</td><td>MMTV-PymT</td><td/><td/><td/><td>&#x2194;</td><td>&#x2194;</td><td>&#x2194;</td><td/><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td>MMTV-TIMP-2 transgene</td><td>MMTV-Wnt1</td><td>&#x2193;</td><td>&#x2193;</td><td>&#x2193;</td><td>&#x2193;</td><td/><td/><td>reduced mean vessel size in tumors</td><td>[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td>TIMP-2 gene therapy</td><td>MMTV-neu</td><td/><td/><td/><td>&#x2193;</td><td>&#x2193;</td><td/><td/><td>[<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic>ApcMin</italic> multiple intestinal neoplasia model in mice with a mutated <italic>Apc</italic> allele; B6, C57BL/6J; <italic>BSw</italic> Black Swiss; <italic>DMBA</italic> 7,12-dimethylbenzanthracene; <italic>ENU N</italic>-ethyl-N-nitrosourea; <italic>MMP</italic> matrix metalloprotease; <italic>MMTV</italic> mouse mammary tumor virus long terminal repeat promoter; <italic>MPA</italic> medroxyprogesterone acetate; <italic>PAI-1</italic> Plg activator inhibitor-1; <italic>Plg</italic> plasminogen; <italic>PymT</italic> polyomavirus middle T antigen; <italic>TIMP</italic> tissue inhibitor of metalloproteases; <italic>uPA</italic> urokinase plasminogen activator; <italic>uPAR</italic> uPA receptor; <italic>WAP</italic> whey acidic protein promoter.</p></table-wrap-foot></table-wrap></p>
      <p>A feature of any transgenic model that is particularly relevant to extracellular proteolysis is the transition from pre-invasive (carcinoma in situ, CIS) to invasive breast carcinoma. Most human pre-invasive lesions are ductal CIS (DCIS), and in these lesions the carcinoma cells accumulate in the ducts confined by the myoepithelial cell layer and the basement membrane. Proteolytic degradation of the basement membrane leads to depolarization of the myoepithelial cells and offers the carcinoma cells access to the surrounding periductal stroma [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In some human breast carcinomas the tumor suppressive myoepithelium surrounding an emerging tumor can persist for a relatively long period of time. In the MMTV-PymT model the late stage tumors resemble human invasive ductal breast cancer, but the myoepithelium is lost very early in tumor progression and it is therefore a poor model of the CIS stage ([<xref ref-type="bibr" rid="CR20">20</xref>] and unpublished data). The lack of an intact myoepithelium, as seen in the MMTV-PymT model, does not necessarily make the neoplastic cells invasive. These lesions fall in the broad category of <italic>mammary intraepithelial neoplasia</italic> (MIN), which includes CIS-like lesions but is used more generally in mouse tumors to describe pre-malignant epithelial cells that have significant nuclear atypia and are surrounded by an intact basement membrane [<xref ref-type="bibr" rid="CR37">37</xref>]. A few transgenic breast cancer models have been described to develop CIS lesions with morphologic similarities to human DCIS and later progress into invasive breast cancer. These include the C3(1)-SV40-T prostate cancer model that also develops mammary lesions [<xref ref-type="bibr" rid="CR38">38</xref>], the WAP-SV40-T model [<xref ref-type="bibr" rid="CR39">39</xref>], and the MMTV-neu models [<xref ref-type="bibr" rid="CR17">17</xref>]. However, the CIS stage has not been the focus of protease intervention studies so far.</p>
    </sec>
    <sec id="Sec4">
      <title>Protease Expression in Transgenic Breast Cancer Models</title>
      <p>Extracellular proteases are generally absent in resting mammary glands but are present as the gland undergoes the pregnancy cycle. The levels of a number of extracellular proteolytic components are particularly upregulated during post-lactational mammary gland involution. These include uPA, tPA, MMPs-2, -3, -9, -11, and their corresponding inhibitors PAI-1 and TIMP-1 [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x2013;<xref ref-type="bibr" rid="CR42">42</xref>]. The upregulated proteases and protease inhibitors are presumably required for the orderly restructuring of the lactating gland to a virgin-like state (discussed later). During breast cancer development, a similar proteolytic program is activated in the diseased gland and extracellular proteases are abundant in invasive breast cancers of both humans and mice. Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref> gives a schematic comparison of the expression patterns of MMP and PA system components in human breast cancer and in the MMTV-PymT transgenic breast cancer model, which has been used to analyze the expression of several extracellular proteases. One study used laser microdissection to isolate cancer cells and stromal cells followed by quantitative RT-PCR to examine the expression level of MMPs and the PA system [<xref ref-type="bibr" rid="CR43">43</xref>]. The study concluded that stromal tissue adjacent to cancer cells expresses higher levels of uPA, PAI-1 and MMPs-2, -3, -11, -13, and -14 than the cancer tissue. The predominantly stromal expression patterns of all these components in the MMTV-PymT model has been confirmed by in situ hybridization [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR43">43</xref>&#x2013;<xref ref-type="bibr" rid="CR46">46</xref>]. Using immunohistochemistry, uPAR expression was found primarily in fibroblasts, endothelial cells, and in some macrophages in the MMTV-PymT model (unpublished data). In situ hybridization was used in another study on MMTV-PymT tumors to determine the expression pattern of four of the membrane-type MMPs: the transmembrane MMPs-14, -15, and -16 and the GPI-linked MMP-17 [<xref ref-type="bibr" rid="CR46">46</xref>]. MMPs-14 and -16 were detected in the stroma whereas MMP-15 was the only protease found predominantly in the epithelium. MMP-17 expression was not observed in the MMTV-PymT tumors. The majority of these findings reflect the mRNA expression data for human breast cancer, since uPA [<xref ref-type="bibr" rid="CR47">47</xref>], PAI-1 [<xref ref-type="bibr" rid="CR48">48</xref>], and MMPs-2 [<xref ref-type="bibr" rid="CR49">49</xref>], -3 [<xref ref-type="bibr" rid="CR50">50</xref>], -11 [<xref ref-type="bibr" rid="CR49">49</xref>], -13 [<xref ref-type="bibr" rid="CR35">35</xref>], and -14 [<xref ref-type="bibr" rid="CR51">51</xref>] all are found predominantly in the stroma (see suppl. data to review by Egeblad and Werb 2002 [<xref ref-type="bibr" rid="CR10">10</xref>]). Immunoreactivity for uPAR is also primarily found in the stroma [<xref ref-type="bibr" rid="CR52">52</xref>]. Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref> provides two examples of this close correlation between human and transgenic mouse tumors: MMP-13 is focally expressed in stromal cells in patient material [<xref ref-type="bibr" rid="CR35">35</xref>] and in MMTV-PymT transgenic tumors [<xref ref-type="bibr" rid="CR43">43</xref>] (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c&#x2013;d). Similarly, the primary uPA inhibitor PAI-1 is expressed in stromal cells in MMTV-PymT mice [<xref ref-type="bibr" rid="CR45">45</xref>] and in breast cancer patients [<xref ref-type="bibr" rid="CR48">48</xref>] (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>e&#x2013;f). The PAI-1-producing stromal cells were identified as myofibroblasts in the human samples. It is of note that this cell type is uncommon in the normal mouse and human glands but is abundant in tumors from both transgenic mice (unpublished data) and breast cancers patients [<xref ref-type="bibr" rid="CR53">53</xref>].
<fig id="Fig2"><label>Figure&#xA0;2</label><caption><p>Expression of MMPs and PA components in breast tumors in humans and in MMTV-PymT transgenic mice. MMPs and PA components are expressed by cancer cells or stromal cells in breast tumors or are present as ubiquitous plasma-derived proteins. The predominant source of each mRNA/protein is illustrated for human ductal breast cancer and for the MMTV-PymT model in mice. Only those proteases and related components that have been analyzed in the MMTV-PymT model are included in the comparison. Only mRNA analyses are included except for uPAR, which was analyzed by immunohistochemistry in both species. The &#x201C;Not detected&#x201D; category includes proteases that were sporadically expressed in the tumors. The data for the MMTV-PymT model: uPA [<xref ref-type="bibr" rid="CR31">31</xref>]; PAI-1 [<xref ref-type="bibr" rid="CR45">45</xref>]; uPAR, MMPs-7, -9, -10 (unpublished data); MMPs-2, -3, -11, -13, -14, uPA, PAI-1 [<xref ref-type="bibr" rid="CR43">43</xref>]; MMPs-14, -15, -16, -17 [<xref ref-type="bibr" rid="CR46">46</xref>]. The data for invasive ductal breast cancer: uPA [<xref ref-type="bibr" rid="CR47">47</xref>]; PAI-1 [<xref ref-type="bibr" rid="CR48">48</xref>]; uPAR [<xref ref-type="bibr" rid="CR52">52</xref>]; MMP-2 [<xref ref-type="bibr" rid="CR49">49</xref>]; MMP-3 [<xref ref-type="bibr" rid="CR50">50</xref>], MMP-7 [<xref ref-type="bibr" rid="CR89">89</xref>]; MMP-9 [<xref ref-type="bibr" rid="CR72">72</xref>]; MMP-10 [<xref ref-type="bibr" rid="CR89">89</xref>]; MMP-11 [<xref ref-type="bibr" rid="CR49">49</xref>]; MMP-13 [<xref ref-type="bibr" rid="CR35">35</xref>]; MMP-14 [<xref ref-type="bibr" rid="CR51">51</xref>].</p></caption><graphic position="anchor" xlink:href="10911_2007_9040_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Figure&#xA0;3</label><caption><p>Examples of protease expression in breast cancer from transgenic mice and humans. Expression of MMP-13 during early invasion in mouse C3(1)-SV40-T breast carcinoma (<bold>a</bold>) and in human ductal carcinoma in situ (DCIS) (<bold>b</bold>). MMP-13 is focally expressed in periductal fibroblast-like cells (arrows in a, a&#x2019;, and b&#x2019;) in areas with early cancer cell invasion (inv) and is not expressed in adjacent non-invasive areas with in situ carcinoma (CIS). Expression of MMP-13 in invasive MMTV-PymT carcinoma (<bold>c</bold>) and in human invasive ductal carcinoma (IDC) of the breast (<bold>d</bold>). Focal expression of MMP-13 is seen in fibroblast-like cells located in the stroma surrounding invasive cancer cells in both mouse and human breast cancers (<italic>arrows</italic> in c and d). Expression of PAI-1 in invasive MMTV-PymT carcinoma (<bold>e</bold>) and in human IDC of the breast (<bold>f</bold>). The expression of PAI-1 is seen in fibroblast-like cells located in the stroma surrounding invasive cancer cells in both the mouse and human breast cancers (<italic>arrows</italic> in e and f). All panels are in situ hybridization using 35S-labeled probes. Panels <bold>a</bold>, <bold>c</bold>&#x2013;<bold>f</bold> are counterstained with haematoxylin and eosin, whereas <bold>b</bold> is combined with pan-cytokeratin immunohistochemistry and (b&#x2019;) with CK14 immunohistochemistry for myoepithelial cells [<xref ref-type="bibr" rid="CR35">35</xref>]. <italic>Bars</italic>: <bold>a</bold>,<bold>c</bold>, 200&#xA0;&#x3BC;m; <bold>b</bold>, 100&#xA0;&#x3BC;m; <bold>d</bold>&#x2013;<bold>f</bold>, 150&#xA0;&#x3BC;m.</p></caption><graphic position="anchor" xlink:href="10911_2007_9040_Fig3_HTML" id="MO3"/></fig></p>
      <p>Recently, the MMTV-Wnt1 model has also been used to study the expression levels of a number of MMPs during mammary tumor formation by RT-PCR and in situ hybridization [<xref ref-type="bibr" rid="CR32">32</xref>]. MMPs-2, -3, -9, -13, and -14 displayed increased expression levels in hyperplastic glands and mammary tumors. MMPs-2, -3, and -9 were exclusively expressed in the stroma, while MMPs-13 and -14 were found predominantly in the cancer cells and to a lesser extent also in stromal cells. Again, most of these MMPs have been reported with similar expression patterns in human breast cancer, although MMPs-13 and -14 are predominantly stromal in ductal breast cancer [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. It is noteworthy that the MMTV-PymT and MMTV-Wnt1 models have broadly similar but not identical localization and expression of MMPs.</p>
      <p>The initial expression of proteases in human breast cancer may be associated with the transition from DCIS to invasive ductal carcinoma. The transition to invasive cancer can be identified histopathologically in some DCIS lesions, particularly facilitated by immunohistochemical staining of myoepithelial cells and intraductal neoplastic cells. Expression studies of MMPs in human DCIS material have shown that MMP-13 is focally upregulated in microinvasive foci (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b) in contrast to MMPs-2, -11, and -14, which are all more broadly expressed in the samples [<xref ref-type="bibr" rid="CR35">35</xref>]. All four of these MMPs are expressed in periductal (myo)fibroblasts, indicating an intense stromal involvement during early invasion. Brummer et al. found that TIMP-1 is also upregulated in areas of early invasion [<xref ref-type="bibr" rid="CR54">54</xref>]. Mimicking the human situation, the C3(1)-SV40-T model develops DCIS-like lesions, in which MMP-13 is upregulated specifically in those DCIS-like structures that show signs of invasion (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a). In human samples, uPA and uPAR are also focally upregulated in areas of microinvasion together with MMP-13, suggesting that plasmin-directed proteolysis coincides with MMP activity in the transition to invasive cancer [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
      <p>Thus, the extracellular proteases expressed in transgenic breast cancer models generally mirror those identified in human breast cancer both in terms of expression and localization. These findings suggest that transgenic models are useful tools for the study of protease involvement in breast cancer invasion and metastasis.</p>
    </sec>
    <sec id="Sec5">
      <title>Functional Studies of Proteases in Breast Cancer Progression</title>
      <sec id="Sec6">
        <title>Proteases in Post-lactational Mammary Gland Involution</title>
        <p>Mammary gland involution following weaning can to some extent be regarded as a surrogate model for the role of proteases in breast cancer invasion due to the extensive tissue remodeling and extracellular proteolysis taking place. The first, reversible stage of involution is prematurely activated in Plg-deficient mice likely due to increased milk stasis during lactation [<xref ref-type="bibr" rid="CR55">55</xref>]. However, the second, protease-dependent and irreversible stage of involution seems to be delayed in Plg-deficient mice [<xref ref-type="bibr" rid="CR5">5</xref>]. Involution is eventually accomplished in Plg-deficient mice probably due to compensating action of other proteases including MMPs. In support of this hypothesis, implantation of TIMP-1 slow release pellets into involuting mammary glands delays alveolar regression [<xref ref-type="bibr" rid="CR40">40</xref>], and likewise TIMP-3 null mice exhibit accelerated involution [<xref ref-type="bibr" rid="CR56">56</xref>]. In contrast, transgenic overexpression of TIMP-1 in <italic>luminal</italic> cells did not provoke an involution phenotype [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR57">57</xref>], which may be a cell-of-origin effect since endogenous TIMP-1 is produced by <italic>stromal</italic> cells during involution [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Similarly, the accelerated involution observed in mice that overexpress MMP-3 in luminal cells [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR59">59</xref>] could be an effect of overexpressing a stromal protein in luminal cells, and is not supported by evidence from MMP-3 null mice that do not show a change in mammary apoptosis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. The fact that the PA system and the MMPs are required for the controlled tissue remodeling of the involuting mammary gland, suggests that it is the inherent proteolytic repertoire of the mammary gland that is reactivated in breast cancers.</p>
      </sec>
      <sec id="Sec7">
        <title>Proteases in Hyperplasia and Carcinogenesis</title>
        <p>The earliest stages of mammary carcinogenesis including the initial genetic alterations in the epithelial cells were previously considered to be independent of the surrounding stroma and extracellular proteolysis. It now seems that the structural integrity of the stroma is an essential factor in preventing carcinogenesis [<xref ref-type="bibr" rid="CR60">60</xref>]. In fact, disruption of the ECM and cellular microenvironment caused by overexpression of MMPs-3, -7 or -14 in the mammary gland is sufficient to initiate mammary epithelial hyperplasia [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR61">61</xref>&#x2013;<xref ref-type="bibr" rid="CR63">63</xref>]. Transgenic mice overexpressing MMP-3 or MMP-14 even develop tumors in the absence of a transgene-supplied oncogene, and a fraction of the tumors undergo malignant transformation [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Similar transgenic overexpression of Plg activators has not been reported for the mammary gland, but a K14-uPA/uPAR double transgene elicits extensive skin hyperplasia [<xref ref-type="bibr" rid="CR64">64</xref>]. The MMP transgenes all direct MMP expression to the mammary epithelium, using either MMTV or WAP promoters. Only MMP-7 is expressed by normal mammary epithelium [<xref ref-type="bibr" rid="CR65">65</xref>], while MMPs-3 and -14 are expressed by the mammary stroma during development and in the mature gland [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Thus, tumor growth and malignancy have only been reported in cases where extracellular proteases were expressed by cells that would not normally produce them. Nevertheless, ectopically expressed proteases act as independent tumor promoters, presumably by compromising the growth-inhibitory role of the stroma, and eventually lead to genetic instability as if they were conventional oncogenes.</p>
        <p>In light of the independent tumorigenic ability of some MMP transgenes, it is not surprising that tumor onset in transgenic breast cancer models is promoted by increased MMP activity and delayed by decreased MMP activity in some studies (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Tumor onset is thus promoted by MMP-7 overexpression in the MMTV-neu model [<xref ref-type="bibr" rid="CR29">29</xref>] and delayed by MMP-11 deficiency in the MMTV-ras model [<xref ref-type="bibr" rid="CR30">30</xref>] or by TIMP-2 overexpression in the MMTV-Wnt1 model [<xref ref-type="bibr" rid="CR32">32</xref>]. Similarly, the incidence of DMBA-induced mammary tumors is reduced in MMP-11-deficient [<xref ref-type="bibr" rid="CR66">66</xref>] and in TIMP-1-overexpressing mice [<xref ref-type="bibr" rid="CR34">34</xref>]. The results of two studies were inconsistent with the general finding: MMP-3 overexpression resulted in reduced rather than increased tumor incidence in the DMBA model [<xref ref-type="bibr" rid="CR33">33</xref>], and MMP-9 deficiency led to increased tumorigenesis in the MMTV-neu model [<xref ref-type="bibr" rid="CR67">67</xref>]. This suggests that some MMPs may have a protective function in mammary tumorigenesis, similar to the protective role of MMP-8 in chemical carcinogenesis of the skin [<xref ref-type="bibr" rid="CR68">68</xref>].</p>
        <p>In contrast to the documented influence of some of the MMPs on tumor initiation, the PA system (including genetic deficiency in Plg [<xref ref-type="bibr" rid="CR44">44</xref>], uPA [<xref ref-type="bibr" rid="CR31">31</xref>], PAI-1 [<xref ref-type="bibr" rid="CR45">45</xref>], or uPAR [unpublished data]) does not affect tumor onset in the MMTV-PymT model. Neither does TIMP-1 overexpression [<xref ref-type="bibr" rid="CR34">34</xref>] or genetic deficiencies of MMPs-2, -7, -9 (Fingleton and Matrisian, personal communication) or MMP-13 (unpublished data) in the MMTV-PymT model. At present it is difficult to determine whether these differences reflect the nature of the different proteases or perhaps that the very early tumor onset, which takes place during puberty in the MMTV-PymT model, is less sensitive to the proteolytic environment.</p>
      </sec>
      <sec id="Sec8">
        <title>Proteases in Tumor Growth and Vascularization</title>
        <p>Mammary hyperplasias and CIS lesions are generally supplied with oxygen and nutrients by the pre-existing vasculature of the mammary gland. Tumor expansion beyond a certain stage requires the formation of new blood vessels. Angiogenesis, the sprouting of new vessels from existing vasculature, depends on proteolytic dissection of the endothelial basement membrane and other ECM components. Endothelial cells penetrate a newly deposited fibrin-rich matrix and use it as a temporary scaffold for vessel structure [<xref ref-type="bibr" rid="CR69">69</xref>]. Accordingly, the fibrinolytic capacity of the PA system is crucial for vascularization in certain experimental settings, and PAI-1 may play a dual role as a protease inhibitor and cell migration mediator [<xref ref-type="bibr" rid="CR3">3</xref>]. In tumors from breast cancer patients, endothelial cells are a considerable source of uPA, PAI-1 and uPAR suggesting a possible role in vascularization [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. This has not been experimentally confirmed in transgenic tumors thus far (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). In the MMTV-PymT model, tumors grow equally fast in the genetic absence or presence of Plg [<xref ref-type="bibr" rid="CR44">44</xref>], uPA [<xref ref-type="bibr" rid="CR31">31</xref>], PAI-1 [<xref ref-type="bibr" rid="CR45">45</xref>] or uPAR (unpublished data), indicating that vascularization is not rate limiting for tumor growth in these cases. It is likely that functional redundancy with other proteolytic components compensates for the absence of a single component in the intact tumor. Even in PAI-1-deficient tumors, vascular density was not significantly different from wild type tumors [<xref ref-type="bibr" rid="CR45">45</xref>]. It is also possible that vascularization of spontaneous tumors can be partially accomplished by endothelial precursor cells in a process termed vasculogenesis that may be independent of proteases or depend on a different subset of proteases [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
        <p>Deficiency of MMP-9 reduces tumor growth in transgenic models of skin or &#x3B2;-cell islet tumors, most likely due to a requirement for MMP-9 to release vascular endothelial growth factor (VEGF) from ECM deposits in order to activate the angiogenic response [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. In human breast tumors MMP-9 is expressed by a subset of inflammatory cells and vascular pericytes, which could suggest a similar role of MMP-9 in breast cancer vascularization [<xref ref-type="bibr" rid="CR72">72</xref>]. However, the evidence is less clear in transgenic breast cancer models (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Final tumor size in MMTV-PymT-transgenic mice is not significantly affected by single gene deficiencies of MMPs-2, -7, -9 (Fingleton and Matrisian, personal communication), or MMP-13 (unpublished data). Deficiency of a single MMP may be compensated by the presence of other MMPs. In contrast, simultaneous inhibition of a number of MMPs through a liver-specific TIMP-1 transgene significantly reduced final tumor size (by 42%) in MMTV-PymT mice [<xref ref-type="bibr" rid="CR34">34</xref>]. Transgenic overexpression of TIMP-2 also caused a significant reduction in tumor growth rate and reduced the mean blood vessel size in MMTV-Wnt1 mammary tumors, providing direct evidence for an effect on vascularization [<xref ref-type="bibr" rid="CR32">32</xref>]. MMP-11 may be important at this stage, since MMP-11-deficient mice develop significantly smaller tumors in the DMBA [<xref ref-type="bibr" rid="CR66">66</xref>] and MMTV-ras [<xref ref-type="bibr" rid="CR30">30</xref>] models. Surprisingly, a broad spectrum MMP inhibitor (galardin) only resulted in a 50% reduction in final tumor size in the MMTV-PymT model (unpublished data). It is possible that some MMPs promote while others inhibit tumor growth and vascularization, and the net effect of inhibiting a whole range of MMPs is rather limited. A protective role against tumor growth and vascularization has been observed in non-mammary models for MMP-3 [<xref ref-type="bibr" rid="CR73">73</xref>] and MMP-19 [<xref ref-type="bibr" rid="CR74">74</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title>Proteases in Cancer Metastasis</title>
        <p>In order to successfully form metastases, cancer cells must enter the lymphatic system or the bloodstream, survive in circulation and arrest in the vasculature, extravasate and finally be able to proliferate in the new tissue. There are several metastasizing transgenic models, but the majority of models metastasize rather infrequently and only when the primary tumors are quite large. In addition to the MMTV-PymT [<xref ref-type="bibr" rid="CR28">28</xref>] and MMTV-neu [<xref ref-type="bibr" rid="CR25">25</xref>] models, very few other breast cancer models metastasize sufficiently to allow rigorous quantification (reviewed in [<xref ref-type="bibr" rid="CR75">75</xref>]). Metastasis can be greatly accelerated by combining e.g. an MMTV-neu model with a second mammary-specific transgene for VEGF or transforming growth factor-&#x3B2;1&#xA0;(TGF&#x3B2;1) [<xref ref-type="bibr" rid="CR75">75</xref>&#x2013;<xref ref-type="bibr" rid="CR77">77</xref>], but these models require more elaborate breeding. Proteases are intimately associated with metastasis. A classic example is the osteolytic bone metastases that are so frequent in breast cancer patients. Breast cancer cells and the resident osteoclasts stimulate each other in a feed-back activation loop. Cancer cells stimulate MMP-dependent degradation of the collagen type I rich bone matrix by osteoclasts [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. As a consequence of bone lysis, latent growth factors are released from their deposits within the bone ECM, and are available to stimulate further cancer cell proliferation. Unfortunately, transgenic models generally metastasize to the lungs and in this way the models do not exactly mimic the organ preference of metastatic breast cancer in humans.</p>
        <p>The PA system plays a unique role in metastasis at least in the MMTV-PymT model that metastasizes to the lungs [<xref ref-type="bibr" rid="CR28">28</xref>] and lymph nodes [<xref ref-type="bibr" rid="CR31">31</xref>] (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). uPA [<xref ref-type="bibr" rid="CR31">31</xref>], PAI-1 [<xref ref-type="bibr" rid="CR45">45</xref>], and uPAR (unpublished data) are all expressed both in the primary tumor and in the lung metastases. Metastasis is significantly reduced in both Plg-deficient and uPA-deficient mice, while these gene deficiencies have no significant effect on the primary MMTV-PymT tumors [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Absence of the specific uPA inhibitor PAI-1 has a slight metastasis-promoting effect, but the difference is not significant perhaps due to the presence of alternative uPA inhibitors [<xref ref-type="bibr" rid="CR45">45</xref>]. Deficiency of uPAR does not significantly affect metastasis in the inbred FVB strain (unpublished data).</p>
        <p>Plg and uPA may promote metastasis due to their fibrinolytic ability. Fibrin-deficient mice have not been studied in a transgenic model, but they are less susceptible to spontaneous metastasis from transplanted tumors [<xref ref-type="bibr" rid="CR80">80</xref>] and lung colonization by tail vein-injected cells [<xref ref-type="bibr" rid="CR81">81</xref>], suggesting that fibrin is important for sustained adhesion of circulating cancer cells in the target organ. Thus, metastasis may depend on an intact and balanced system of fibrin formation and fibrinolysis. Alternatively, Plg and uPA may promote metastasis by releasing growth factors from the ECM. Overexpression of relevant ECM-sequestered growth factors promotes breast cancer progression and metastasis in transgenic models [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. These growth factors include the possible plasmin substrates VEGF, TGF&#x3B2;, and FGF (fibroblast growth factor), as well as the possible uPA substrate HGF (hepatocyte growth factor).</p>
        <p>There is also considerable evidence linking the MMPs to invasion and metastasis (reviewed in [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]). In MMTV-PymT mice treated with the broad spectrum MMP inhibitor galardin, the average lung metastasis volume is reduced by approximately 99%, in the context of primary tumors that are only reduced by half (unpublished data). Metastasis incidence is also reduced in MMTV-PymT mice that overexpress TIMP-1 through a liver-specific transgene, but the reduction is less pronounced and is absent with a mammary gland-specific TIMP-1 transgene [<xref ref-type="bibr" rid="CR34">34</xref>]. It will take a considerable effort to define which MMPs are responsible for the metastasis reduction observed with these inhibitors. MMP-9 deficiency results in reduced metastasis in the MMTV-PymT model, although this phenotype was mouse strain dependent (Fingleton and Matrisian, personal communication). Deficiency of MMP-2, which is abundantly expressed in the stroma of MMTV-PymT tumors [<xref ref-type="bibr" rid="CR43">43</xref>], also results in reduced metastasis in the same model (Fingleton and Matrisian, personal communication). MMPs-2 and -9 have previously been associated with invasion and metastasis in a number of studies [<xref ref-type="bibr" rid="CR84">84</xref>]. In contrast, there is no effect on metastasis in MMTV-PymT mice that are deficient in either MMP-7 (Fingleton and Matrisian, personal communication) or MMP-13 (unpublished data). Similarly, overexpression of MMP-7 in mammary glands has no effect on lung metastasis in the MMTV-neu model [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
        <p>MMP-11 may play an unexpected role in actually preventing metastasis. In the MMTV-ras model, MMP-11 deficiency results in a higher number of metastases despite a lower number and volume of primary tumors [<xref ref-type="bibr" rid="CR30">30</xref>]. Apparently, the transition to invasive carcinoma is greatly accelerated in the MMP-11 null mice, indicative of a protective function of MMP-11. A similar protective role against metastasis has been reported in non-mammary models for MMP-3 [<xref ref-type="bibr" rid="CR73">73</xref>] and MMP-12 [<xref ref-type="bibr" rid="CR85">85</xref>]. Thus, while the general MMP inhibitor galardin has a large inhibitory effect on metastasis, several single MMP knock-out studies report no effect or even the opposite effect on metastasis in breast cancer models. This demonstrates the potential of MMP inhibitors in preventing spontaneous metastasis but also underlines the necessity of evaluating a second generation of MMP inhibitors for clinical trials that are more specific than previous compounds. Transgenic models with a well-characterized involvement of MMPs in metastasis could be a useful tool in testing such compounds.</p>
      </sec>
    </sec>
    <sec id="Sec10" sec-type="conclusion">
      <title>Conclusion and Future Perspectives</title>
      <p>Transgenic breast cancer models are invaluable research tools because they recapitulate the entire process from the initial genetic events in normal cells to metastatic disease. Furthermore, the very similar expression patterns of extracellular proteases in human and mouse breast cancer samples suggest that transgenic mouse models are ideally suited to study the role of proteases in carcinogenesis and the progression to invasion and metastasis.</p>
      <p>We have only begun to examine gene deficiencies and transgenic overexpression of the various PA and MMP components in transgenic models. The studies that have been performed so far suggest that no single MMP or PA system component is likely to be all-important for any stage in tumor progression. Practically all of the protease intervention studies report partial phenotypes such as <italic>delayed</italic> carcinogenesis, <italic>slower</italic> tumor growth or <italic>reduced</italic> metastasis, if they report any phenotype at all. The absence of any absolute phenotypes, such as <italic>prevention</italic> of metastasis, suggests that many of the proteases have mutually overlapping functions. The challenge for developing novel therapeutics in the future will be to identify those proteases that can be targeted simultaneously to obtain a synergistic tumor-suppressive effect.</p>
      <p>Another area that has so far only been thoroughly examined in one or two transgenic models is the expression patterns of proteases. Using protease array data, it may be possible to draw some more detailed parallels between individual mouse models and certain histopathological subtypes of human breast cancers. It is very possible that the collective of transgenic breast cancer models available, rather than any single transgenic, will be needed to adequately model the heterogenous human disease. Another open question is whether certain proteases or inhibitors are up- or downregulated in response to certain gene deficiencies. This may provide vital information on functional overlap between individual proteases.</p>
      <p>Transgenic breast cancer mice may prove to be very reliable models not only for basic research but also for testing experimental anti-proteolytic therapeutics, due to the high degree of similarity with human breast cancer. However, the transgenic models also present some significant challenges. A key issue is that the experimental drug has to cross-react with the mouse version of the protease. Therefore, it may be necessary in some cases to develop two drugs in parallel, one for each species. Due to the extracellular nature of the PA and MMP systems, these represent excellent targets for therapeutic monoclonal antibodies. An elegant method for targeting extracellular proteases in transgenic mice is the development of monoclonal anti-mouse antibodies by immunizing protease-deficient mice with the target protease. In conclusion, transgenic breast cancer models will further the identification of extracellular proteases critical to cancer invasion and metastasis, and aid the development of new agents against the spread of cancer.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful to Drs. Barbara Fingleton and Lynn Matrisian for sharing unpublished results, and to Dr. Fritz Rank for assistance with histopathological evaluation of tumor samples. The assistance of Mr. John Post in creating the artwork is greatly appreciated. This work was supported by grants from the Danish Cancer Research Foundation, the Copenhagen Hospital Corporation, the &#x201C;Grosserer Alfred Nielsen og hustrus&#x201D; foundation, the European Commission grant LSHC-CT-2003-503297, and the European Union research training grant for mammary gland biology RTN-2002-00246.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>ECM degrading proteases and tissue remodelling in the mammary gland</article-title>
          <source>BioEssays</source>
          <year>2005</year>
          <volume>27</volume>
          <fpage>894</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="doi">10.1002/bies.20281</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. BioEssays 2005;27:894&#x2013;903. <pub-id pub-id-type="pmid">16108064</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnsen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>R&#xF8;mer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Almholt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dan&#xF8;</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation</article-title>
          <source>Curr Opin Cell Biol</source>
          <year>1998</year>
          <volume>10</volume>
          <fpage>667</fpage>
          <lpage>671</lpage>
          <pub-id pub-id-type="doi">10.1016/S0955-0674(98)80044-6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Johnsen M, Lund LR, R&#xF8;mer J, Almholt K, Dan&#xF8; K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667&#x2013;71. <pub-id pub-id-type="pmid">9818179</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andreasen</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Egelund</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>The plasminogen activation system in tumor growth, invasion, and metastasis</article-title>
          <source>Cell Mol Life Sci</source>
          <year>2000</year>
          <volume>57</volume>
          <fpage>25</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1007/s000180050497</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25&#x2013;40. <pub-id pub-id-type="pmid">10949579</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bass</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Cellular mechanisms regulating non-haemostatic plasmin generation</article-title>
          <source>Biochem Soc Trans</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>189</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.1042/BST0300189</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bass R, Ellis V. Cellular mechanisms regulating non-haemostatic plasmin generation. Biochem Soc Trans 2002;30:189&#x2013;94. <pub-id pub-id-type="pmid">12023849</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Bj&#xF8;rn</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Sternlicht</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Solberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Usher</surname>
              <given-names>PA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lactational competence and involution of the mouse mammary gland require plasminogen</article-title>
          <source>Development</source>
          <year>2000</year>
          <volume>127</volume>
          <fpage>4481</fpage>
          <lpage>4492</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lund LR, Bj&#xF8;rn SF, Sternlicht MD, Nielsen BS, Solberg H, Usher PA, et al. Lactational competence and involution of the mouse mammary gland require plasminogen. Development 2000;127:4481&#x2013;92. <pub-id pub-id-type="pmid">11003846</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>R&#xF8;mer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bugge</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Pyke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Flick</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Degen</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impaired wound healing in mice with a disrupted plasminogen gene</article-title>
          <source>Nat Med</source>
          <year>1996</year>
          <volume>2</volume>
          <fpage>287</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="doi">10.1038/nm0396-287</pub-id>
        </citation>
        <citation citation-type="display-unstructured">R&#xF8;mer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996;2:287&#x2013;92. <pub-id pub-id-type="pmid">8612226</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rinkenberger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dan&#xF8;</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>A functional overlap of plasminogen and MMPs regulates vascularization during placental development</article-title>
          <source>Development</source>
          <year>2003</year>
          <volume>130</volume>
          <fpage>4439</fpage>
          <lpage>4450</lpage>
          <pub-id pub-id-type="doi">10.1242/dev.00642</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Solberg H, Rinkenberger J, Dan&#xF8; K, Werb Z, Lund LR. A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 2003;130:4439&#x2013;50. <pub-id pub-id-type="pmid">12900459</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Stoop</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Ploug</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Almholt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lilla</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice</article-title>
          <source>EMBO J</source>
          <year>2006</year>
          <volume>25</volume>
          <fpage>2686</fpage>
          <lpage>2697</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.emboj.7601173</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lund LR, Green KA, Stoop AA, Ploug M, Almholt K, Lilla J, et al. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J 2006;25:2686&#x2013;97. <pub-id pub-id-type="pmid">16763560</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selvarajan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Craik</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation</article-title>
          <source>Nat Cell Biol</source>
          <year>2001</year>
          <volume>3</volume>
          <fpage>267</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="doi">10.1038/35060059</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Selvarajan S, Lund LR, Takeuchi T, Craik CS, Werb Z. A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol 2001;3:267&#x2013;75. <pub-id pub-id-type="pmid">11231576</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egeblad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>New functions for the matrix metalloproteinases in cancer progression</article-title>
          <source>Nat Rev Cancer</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>161</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc745</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161&#x2013;74. <pub-id pub-id-type="pmid">11990853</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jodele</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blavier</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>DeClerck</surname>
              <given-names>YA</given-names>
            </name>
          </person-group>
          <article-title>Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression</article-title>
          <source>Cancer Metastasis Rev</source>
          <year>2006</year>
          <volume>25</volume>
          <fpage>35</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1007/s10555-006-7887-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 2006;25:35&#x2013;43. <pub-id pub-id-type="pmid">16680570</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fata</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Leco</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Moorehead</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Khokha</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>TIMP-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development</article-title>
          <source>Dev Biol</source>
          <year>1999</year>
          <volume>211</volume>
          <fpage>238</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="doi">10.1006/dbio.1999.9313</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fata JE, Leco KJ, Moorehead RA, Martin DC, Khokha R. TIMP-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Dev Biol 1999;211:238&#x2013;54. <pub-id pub-id-type="pmid">10395785</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiseman</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Sternlicht</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Mott</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bissell</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis</article-title>
          <source>J Cell Biol</source>
          <year>2003</year>
          <volume>162</volume>
          <fpage>1123</fpage>
          <lpage>1133</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.200302090</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wiseman BS, Sternlicht MD, Lund LR, Alexander CM, Mott J, Bissell MJ, et al. Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol 2003;162:1123&#x2013;33. <pub-id pub-id-type="pmid">12975354</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stickens</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Behonick</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Ortega</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Heyer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hartenstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Altered endochondral bone development in matrix metalloproteinase 13-deficient mice</article-title>
          <source>Development</source>
          <year>2004</year>
          <volume>131</volume>
          <fpage>5883</fpage>
          <lpage>5895</lpage>
          <pub-id pub-id-type="doi">10.1242/dev.01461</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004;131:5883&#x2013;95. <pub-id pub-id-type="pmid">15539485</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>R&#xF8;mer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bugge</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Frandsen</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Degen</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Functional overlap between two classes of matrix-degrading proteases in wound healing</article-title>
          <source>EMBO J</source>
          <year>1999</year>
          <volume>18</volume>
          <fpage>4645</fpage>
          <lpage>4656</lpage>
          <pub-id pub-id-type="doi">10.1093/emboj/18.17.4645</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lund LR, R&#xF8;mer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999;18:4645&#x2013;56. <pub-id pub-id-type="pmid">10469644</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexander</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Selvarajan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mudgett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Stromelysin-1 regulates adipogenesis during mammary gland involution</article-title>
          <source>J Cell Biol</source>
          <year>2001</year>
          <volume>152</volume>
          <fpage>693</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.152.4.693</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Alexander CM, Selvarajan S, Mudgett J, Werb Z. Stromelysin-1 regulates adipogenesis during mammary gland involution. J Cell Biol 2001;152:693&#x2013;703. <pub-id pub-id-type="pmid">11266461</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardiff</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Wellings</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>The comparative pathology of human and mouse mammary glands</article-title>
          <source>J Mammary Gland Biol Neoplasia</source>
          <year>1999</year>
          <volume>4</volume>
          <fpage>105</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1018712905244</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia 1999;4:105&#x2013;22. <pub-id pub-id-type="pmid">10219910</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hovey</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>McFadden</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Akers</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Regulation of mammary gland growth and morphogenesis by the mammary fat pad: a species comparison</article-title>
          <source>J Mammary Gland Biol Neoplasia</source>
          <year>1999</year>
          <volume>4</volume>
          <fpage>53</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1018704603426</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hovey RC, McFadden TB, Akers RM. Regulation of mammary gland growth and morphogenesis by the mammary fat pad: a species comparison. J Mammary Gland Biol Neoplasia 1999;4:53&#x2013;68. <pub-id pub-id-type="pmid">10219906</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Metcalfe</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Gilmore</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Klinowska</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Valentijn</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Developmental regulation of Bcl-2 family protein expression in the involuting mammary gland</article-title>
          <source>J Cell Sci</source>
          <year>1999</year>
          <volume>112</volume>
          <fpage>1771</fpage>
          <lpage>1783</lpage>
        </citation>
        <citation citation-type="display-unstructured">Metcalfe AD, Gilmore A, Klinowska T, Oliver J, Valentijn AJ, Brown R, et al. Developmental regulation of Bcl-2 family protein expression in the involuting mammary gland. J Cell Sci 1999;112:1771&#x2013;83. <pub-id pub-id-type="pmid">10318769</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Whitney</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>WJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases</article-title>
          <source>Am J Pathol</source>
          <year>2003</year>
          <volume>163</volume>
          <fpage>2113</fpage>
          <lpage>2126</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113&#x2013;26. <pub-id pub-id-type="pmid">14578209</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ploug</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>&#xD8;stergaard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>G&#xE5;rdsvoll</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kovalski</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Holst-Hansen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation</article-title>
          <source>Biochemistry</source>
          <year>2001</year>
          <volume>40</volume>
          <fpage>12157</fpage>
          <lpage>12168</lpage>
          <pub-id pub-id-type="doi">10.1021/bi010662g</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ploug M, &#xD8;stergaard S, G&#xE5;rdsvoll H, Kovalski K, Holst-Hansen C, Holm A, et al. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001;40:12157&#x2013;68. <pub-id pub-id-type="pmid">11580291</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almholt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Johnsen</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Stromal cell involvement in cancer</article-title>
          <source>Recent Results Cancer Res</source>
          <year>2003</year>
          <volume>162</volume>
          <fpage>31</fpage>
          <lpage>42</lpage>
        </citation>
        <citation citation-type="display-unstructured">Almholt K, Johnsen M. Stromal cell involvement in cancer. Recent Results Cancer Res 2003;162:31&#x2013;42. <pub-id pub-id-type="pmid">12790319</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shen</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>Transgenic mouse models for the prevention of breast cancer</article-title>
          <source>Mutat Res</source>
          <year>2005</year>
          <volume>576</volume>
          <fpage>93</fpage>
          <lpage>110</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shen Q, Brown PH. Transgenic mouse models for the prevention of breast cancer. Mutat Res 2005;576:93&#x2013;110. <pub-id pub-id-type="pmid">15888345</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardiff</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Anver</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Gusterson</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Hennighausen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Merino</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting</article-title>
          <source>Oncogene</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>968</fpage>
          <lpage>988</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1203277</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968&#x2013;88. <pub-id pub-id-type="pmid">10713680</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guy</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Schaller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parsons</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Cardiff</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1992</year>
          <volume>89</volume>
          <fpage>10578</fpage>
          <lpage>10582</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.89.22.10578</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578&#x2013;82. <pub-id pub-id-type="pmid">1359541</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sinn</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Pattengale</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tepler</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Leder</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Coexpression of MMTV/v-Ha-<italic>ras</italic> and MMTV/c-<italic>myc</italic> genes in transgenic mice: synergistic action of oncogenes in vivo</article-title>
          <source>Cell</source>
          <year>1987</year>
          <volume>49</volume>
          <fpage>465</fpage>
          <lpage>475</lpage>
          <pub-id pub-id-type="doi">10.1016/0092-8674(87)90449-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987;49:465&#x2013;75. <pub-id pub-id-type="pmid">3032456</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsukamoto</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Grosschedl</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Guzman</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Parslow</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Varmus</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice</article-title>
          <source>Cell</source>
          <year>1988</year>
          <volume>55</volume>
          <fpage>619</fpage>
          <lpage>625</lpage>
          <pub-id pub-id-type="doi">10.1016/0092-8674(88)90220-6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988;55:619&#x2013;25. <pub-id pub-id-type="pmid">3180222</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guy</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Cardiff</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease</article-title>
          <source>Mol Cell Biol</source>
          <year>1992</year>
          <volume>12</volume>
          <fpage>954</fpage>
          <lpage>961</lpage>
        </citation>
        <citation citation-type="display-unstructured">Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954&#x2013;61. <pub-id pub-id-type="pmid">1312220</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rudolph-Owen</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Matrisian</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis</article-title>
          <source>Cancer Res</source>
          <year>1998</year>
          <volume>58</volume>
          <fpage>5500</fpage>
          <lpage>5506</lpage>
        </citation>
        <citation citation-type="display-unstructured">Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 1998;58:5500&#x2013;6. <pub-id pub-id-type="pmid">9850086</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andarawewa</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Boulay</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Masson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mathelin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stoll</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tomasetto</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression</article-title>
          <source>Cancer Res</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>5844</fpage>
          <lpage>5849</lpage>
        </citation>
        <citation citation-type="display-unstructured">Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 2003;63:5844&#x2013;9. <pub-id pub-id-type="pmid">14522908</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almholt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Rygaard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Dan&#xF8;</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>R&#xF8;mer</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice</article-title>
          <source>Int J Cancer</source>
          <year>2005</year>
          <volume>113</volume>
          <fpage>525</fpage>
          <lpage>532</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.20631</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Almholt K, Lund LR, Rygaard J, Nielsen BS, Dan&#xF8; K, R&#xF8;mer J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005;113:525&#x2013;32. <pub-id pub-id-type="pmid">15472905</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blavier</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lazaryev</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dorey</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Shackleford</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>DeClerck</surname>
              <given-names>YA</given-names>
            </name>
          </person-group>
          <article-title>Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis</article-title>
          <source>Cancer Res</source>
          <year>2006</year>
          <volume>66</volume>
          <fpage>2691</fpage>
          <lpage>2699</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2919</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Blavier L, Lazaryev A, Dorey F, Shackleford GM, DeClerck YA. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Res 2006;66:2691&#x2013;9. <pub-id pub-id-type="pmid">16510589</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Witty</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Lempka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Coffey</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Matrisian</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis</article-title>
          <source>Cancer Res</source>
          <year>1995</year>
          <volume>55</volume>
          <fpage>1401</fpage>
          <lpage>1406</lpage>
        </citation>
        <citation citation-type="display-unstructured">Witty JP, Lempka T, Coffey RJ, Jr., Matrisian LM. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 1995;55:1401&#x2013;6. <pub-id pub-id-type="pmid">7882342</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamazaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Akahane</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Buck</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshiji</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Schoeffner</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice</article-title>
          <source>Carcinogenesis</source>
          <year>2004</year>
          <volume>25</volume>
          <fpage>1735</fpage>
          <lpage>1746</lpage>
          <pub-id pub-id-type="doi">10.1093/carcin/bgh181</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yamazaki M, Akahane T, Buck T, Yoshiji H, Gomez DE, Schoeffner DJ, et al. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Carcinogenesis 2004;25:1735&#x2013;46. <pub-id pub-id-type="pmid">15166086</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Rank</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Balbin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vizoso</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas</article-title>
          <source>Cancer Res</source>
          <year>2001</year>
          <volume>61</volume>
          <fpage>7091</fpage>
          <lpage>7100</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nielsen BS, Rank F, L&#xF3;pez JM, Balbin M, Vizoso F, Lund LR, et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001;61:7091&#x2013;100. <pub-id pub-id-type="pmid">11585740</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="other">Nielsen BS, Rank F, Illemann M, Lund LR, Dan&#xF8; K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ co-express urokinase and urokinase receptor. Int J Cancer (in press).</citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardiff</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Moghanaki</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Genetically engineered mouse models of mammary intraepithelial neoplasia</article-title>
          <source>J Mammary Gland Biol Neoplasia</source>
          <year>2000</year>
          <volume>5</volume>
          <fpage>421</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1009534129331</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cardiff RD, Moghanaki D, Jensen RA. Genetically engineered mouse models of mammary intraepithelial neoplasia. J Mammary Gland Biol Neoplasia 2000;5:421&#x2013;37. <pub-id pub-id-type="pmid">14973386</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Yoshidome</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Jorcyk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Anver</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma</article-title>
          <source>Oncogene</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>1020</fpage>
          <lpage>1027</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1203280</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000;19:1020&#x2013;7. <pub-id pub-id-type="pmid">10713685</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schulze-Garg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>L&#xF6;hler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gocht</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Deppert</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland</article-title>
          <source>Oncogene</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>1028</fpage>
          <lpage>1037</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1203281</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schulze-Garg C, L&#xF6;hler J, Gocht A, Deppert W. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000;19:1028&#x2013;37. <pub-id pub-id-type="pmid">10713686</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Talhouk</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Bissell</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution</article-title>
          <source>J Cell Biol</source>
          <year>1992</year>
          <volume>118</volume>
          <fpage>1271</fpage>
          <lpage>1282</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.118.5.1271</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J CellBiol 1992;118:1271&#x2013;82. <pub-id pub-id-type="pmid">1512297</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lefebvre</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Limacher</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Hutin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wendling</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>LeMeur</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis</article-title>
          <source>J Cell Biol</source>
          <year>1992</year>
          <volume>119</volume>
          <fpage>997</fpage>
          <lpage>1002</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.119.4.997</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lefebvre O, Wolf C, Limacher JM, Hutin P, Wendling C, LeMeur M, et al. The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis. J Cell Biol 1992;119:997&#x2013;1002. <pub-id pub-id-type="pmid">1429845</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>R&#xF8;mer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thomasset</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Solberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pyke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bissell</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways</article-title>
          <source>Development</source>
          <year>1996</year>
          <volume>122</volume>
          <fpage>181</fpage>
          <lpage>193</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lund LR, R&#xF8;mer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996;122:181&#x2013;93. <pub-id pub-id-type="pmid">8565829</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pedersen</surname>
              <given-names>TX</given-names>
            </name>
            <name>
              <surname>Pennington</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Almholt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>DR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas</article-title>
          <source>Carcinogenesis</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>1233</fpage>
          <lpage>1240</lpage>
          <pub-id pub-id-type="doi">10.1093/carcin/bgi065</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pedersen TX, Pennington CJ, Almholt K, Christensen IJ, Nielsen BS, Edwards DR, et al. Protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis 2005;26:1233&#x2013;40. <pub-id pub-id-type="pmid">15760918</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bugge</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Kombrinck</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Holmb&#xE4;ck</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Drew</surname>
              <given-names>AF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice</article-title>
          <source>Oncogene</source>
          <year>1998</year>
          <volume>16</volume>
          <fpage>3097</fpage>
          <lpage>3104</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1201869</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmb&#xE4;ck K, Drew AF, et al. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998;16:3097&#x2013;104. <pub-id pub-id-type="pmid">9671388</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almholt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Frandsen</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Br&#xFC;nner</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dan&#xF8;</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Johnsen</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice</article-title>
          <source>Oncogene</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>4389</fpage>
          <lpage>4397</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1206601</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Almholt K, Nielsen BS, Frandsen TL, Br&#xFC;nner N, Dan&#xF8; K, Johnsen M. Metastasis of transgenic breast cancer in plasminogenactivator inhibitor-1 gene-deficient mice. Oncogene 2003;22:4389&#x2013;97. <pub-id pub-id-type="pmid">12853975</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szabova</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Birkedal-Hansen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Holmbeck</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland</article-title>
          <source>J Cell Physiol</source>
          <year>2005</year>
          <volume>205</volume>
          <fpage>123</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="doi">10.1002/jcp.20385</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Szabova L, Yamada SS, Birkedal-Hansen H, Holmbeck K. Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland. J Cell Physiol 2005;205:123&#x2013;32. <pub-id pub-id-type="pmid">15895410</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Sehested</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Duun</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rank</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Timshel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rygaard</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer</article-title>
          <source>Lab Invest</source>
          <year>2001</year>
          <volume>81</volume>
          <fpage>1485</fpage>
          <lpage>1502</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nielsen BS, Sehested M, Duun S, Rank F, Timshel S, Rygaard J, et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001;81:1485&#x2013;502. <pub-id pub-id-type="pmid">11706057</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Offersen</surname>
              <given-names>BV</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>H&#xF8;yer-Hansen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rank</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hamilton-Dutoit</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Overgaard</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The myofibroblast is the predominant plasminogen activator inhibitor-1 expressing cell type in human breast carcinomas</article-title>
          <source>Am J Pathol</source>
          <year>2003</year>
          <volume>163</volume>
          <fpage>1887</fpage>
          <lpage>1899</lpage>
        </citation>
        <citation citation-type="display-unstructured">Offersen BV, Nielsen BS, H&#xF8;yer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, et al. The myofibroblast is the predominant plasminogen activator inhibitor-1 expressing cell type in human breast carcinomas. Am J Pathol 2003;163:1887&#x2013;99. <pub-id pub-id-type="pmid">14578188</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolf</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rouyer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Adida</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Loriot</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bellocq</surname>
              <given-names>J-P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1993</year>
          <volume>90</volume>
          <fpage>1843</fpage>
          <lpage>1847</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.90.5.1843</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq J-P, et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993;90:1843&#x2013;7. <pub-id pub-id-type="pmid">8446598</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakopoulou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Giannopoulou</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gakiopoulou</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liapis</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tzonou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Davaris</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features</article-title>
          <source>Hum Pathol</source>
          <year>1999</year>
          <volume>30</volume>
          <fpage>436</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="doi">10.1016/S0046-8177(99)90120-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris PS. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999;30:436&#x2013;42. <pub-id pub-id-type="pmid">10208466</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bellocq</surname>
              <given-names>J-P</given-names>
            </name>
            <name>
              <surname>Rouyer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chenard</surname>
              <given-names>M-P</given-names>
            </name>
            <name>
              <surname>Rio</surname>
              <given-names>M-C</given-names>
            </name>
            <name>
              <surname>Chambon</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1995</year>
          <volume>92</volume>
          <fpage>2730</fpage>
          <lpage>2734</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.92.7.2730</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Okada A, Bellocq J-P, Rouyer N, Chenard M-P, Rio M-C, Chambon P, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A 1995;92:2730&#x2013;4. <pub-id pub-id-type="pmid">7708715</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pyke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gr&#xE6;m</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ralfki&#xE6;r</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>R&#xF8;nne</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>H&#xF8;yer-Hansen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Br&#xFC;nner</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma</article-title>
          <source>Cancer Res</source>
          <year>1993</year>
          <volume>53</volume>
          <fpage>1911</fpage>
          <lpage>1915</lpage>
        </citation>
        <citation citation-type="display-unstructured">Pyke C, Gr&#xE6;m N, Ralfki&#xE6;r E, R&#xF8;nne E, H&#xF8;yer-Hansen G, Br&#xFC;nner N, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911&#x2013;5. <pub-id pub-id-type="pmid">8385573</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sappino</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Skalli</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schurch</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gabbiani</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues</article-title>
          <source>Int J Cancer</source>
          <year>1988</year>
          <volume>41</volume>
          <fpage>707</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.2910410512</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sappino AP, Skalli O, Jackson B, Schurch W, Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer 1988;41:707&#x2013;12. <pub-id pub-id-type="pmid">2835323</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brummer</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Athar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Riethdorf</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>L&#xF6;ning</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Herbst</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study</article-title>
          <source>Virchows Arch</source>
          <year>1999</year>
          <volume>435</volume>
          <fpage>566</fpage>
          <lpage>573</lpage>
          <pub-id pub-id-type="doi">10.1007/s004280050442</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Brummer O, Athar S, Riethdorf L, L&#xF6;ning T, Herbst H. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 1999;435:566&#x2013;73. <pub-id pub-id-type="pmid">10628798</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Castellino</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>R&#xF8;mer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>Lack of plasminogen leads to milk stasis and premature mammary gland involution during lactation</article-title>
          <source>Dev Biol</source>
          <year>2006</year>
          <volume>299</volume>
          <fpage>164</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ydbio.2006.07.021</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Green KA, Nielsen BS, Castellino FJ, R&#xF8;mer J, Lund LR. Lack of plasminogen leads to milk stasis and premature mammary gland involution during lactation. Dev Biol 2006;299:164&#x2013;75. <pub-id pub-id-type="pmid">16949567</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fata</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Leco</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Voura</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Waterhouse</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Accelerated apoptosis in the <italic>Timp-3</italic>-deficient mammary gland</article-title>
          <source>J Clin Invest</source>
          <year>2001</year>
          <volume>108</volume>
          <fpage>831</fpage>
          <lpage>841</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200113171</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G, et al. Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest 2001;108:831&#x2013;41. <pub-id pub-id-type="pmid">11560952</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexander</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Bissell</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene</article-title>
          <source>J Cell Biol</source>
          <year>1996</year>
          <volume>135</volume>
          <fpage>1669</fpage>
          <lpage>1677</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.135.6.1669</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Alexander CM, Howard EW, Bissell MJ, Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J Cell Biol 1996;135:1669&#x2013;77. <pub-id pub-id-type="pmid">8978831</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Strange</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Friis</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Djonov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Altermatt</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Saurer</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of stromelysin-1 and TIMP-1 in the involuting mammary gland and in early invasive tumors of the mouse</article-title>
          <source>Int J Cancer</source>
          <year>1994</year>
          <volume>59</volume>
          <fpage>560</fpage>
          <lpage>568</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.2910590421</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Li F, Strange R, Friis RR, Djonov V, Altermatt HJ, Saurer S, et al. Expression of stromelysin-1 and TIMP-1 in the involuting mammary gland and in early invasive tumors of the mouse. Int J Cancer 1994;59:560&#x2013;8. <pub-id pub-id-type="pmid">7960227</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sympson</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Talhouk</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Clift</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Bissell</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression</article-title>
          <source>J Cell Biol</source>
          <year>1994</year>
          <volume>125</volume>
          <fpage>681</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.125.3.681</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ, et al. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 1994;125:681&#x2013;93. <pub-id pub-id-type="pmid">8175886</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Radisky</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Bissell</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Matrix metalloproteinase-induced genomic instability</article-title>
          <source>Curr Opin Genet Dev</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>45</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1016/j.gde.2005.12.011</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Radisky DC, Bissell MJ. Matrix metalloproteinase-induced genomic instability. Curr Opin Genet Dev 2006;16:45&#x2013;50. <pub-id pub-id-type="pmid">16377172</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Witty</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Matrisian</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development</article-title>
          <source>Mol Biol Cell</source>
          <year>1995</year>
          <volume>6</volume>
          <fpage>1287</fpage>
          <lpage>1303</lpage>
        </citation>
        <citation citation-type="display-unstructured">Witty JP, Wright JH, Matrisian LM. Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. Mol Biol Cell 1995;6:1287&#x2013;303. <pub-id pub-id-type="pmid">8573787</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sternlicht</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lochter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sympson</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Huey</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rougier</surname>
              <given-names>J-P</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>JW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis</article-title>
          <source>Cell</source>
          <year>1999</year>
          <volume>98</volume>
          <fpage>137</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81009-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier J-P, Gray JW, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137&#x2013;46. <pub-id pub-id-type="pmid">10428026</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ha</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Moon</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Ryoo</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>TH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice</article-title>
          <source>Cancer Res</source>
          <year>2001</year>
          <volume>61</volume>
          <fpage>984</fpage>
          <lpage>990</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ha HY, Moon HB, Nam MS, Lee JW, Ryoo ZY, Lee TH, et al. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res 2001;61:984&#x2013;90. <pub-id pub-id-type="pmid">11221894</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bolon</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>H-M</given-names>
            </name>
            <name>
              <surname>Charron</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wohlwend</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vassalli</surname>
              <given-names>J-D</given-names>
            </name>
          </person-group>
          <article-title>Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression</article-title>
          <source>Am J Pathol</source>
          <year>2004</year>
          <volume>164</volume>
          <fpage>2299</fpage>
          <lpage>2304</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bolon I, Zhou H-M, Charron Y, Wohlwend A, Vassalli J-D. Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am J Pathol 2004;164:2299&#x2013;304. <pub-id pub-id-type="pmid">15161662</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saarialho-Kere</surname>
              <given-names>UK</given-names>
            </name>
            <name>
              <surname>Crouch</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Parks</surname>
              <given-names>WC</given-names>
            </name>
          </person-group>
          <article-title>trix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium</article-title>
          <source>Invest Dermatol</source>
          <year>1995</year>
          <volume>105</volume>
          <fpage>190</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1111/1523-1747.ep12317104</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Saarialho-Kere UK, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995;105:190&#x2013;6. </citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lefebvre</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>No&#xEB;l</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>El Fahime</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chenard</surname>
              <given-names>M-P</given-names>
            </name>
            <name>
              <surname>Wendling</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy</article-title>
          <source>J Cell Biol</source>
          <year>1998</year>
          <volume>140</volume>
          <fpage>1535</fpage>
          <lpage>1541</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.140.6.1535</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Masson R, Lefebvre O, No&#xEB;l A, El Fahime M, Chenard M-P, Wendling C, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535&#x2013;41. <pub-id pub-id-type="pmid">9508784</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="other">Kenny PA, Rizki A. 42nd Annual Meeting of the American Society for Cell Biology, San Francisco, California, USA, 14&#x2013;18 December 2002. Breast Cancer Res 2003;5:147&#x2013;53.</citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balb&#xED;n</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fueyo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tester</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Pend&#xE1;s</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Pitiot</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Astudillo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Loss of collagenase-2 confers increased skin tumor susceptibility to male mice</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>35</volume>
          <fpage>252</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1249</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Balb&#xED;n M, Fueyo A, Tester AM, Pend&#xE1;s AM, Pitiot AS, Astudillo A, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252&#x2013;7. <pub-id pub-id-type="pmid">14517555</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dvorak</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Detmar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dvorak</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis</article-title>
          <source>Am J Pathol</source>
          <year>1995</year>
          <volume>146</volume>
          <fpage>1029</fpage>
          <lpage>1039</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029&#x2013;39. <pub-id pub-id-type="pmid">7538264</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coussens</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Tinkle</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Hanahan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Werb</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis</article-title>
          <source>Cell</source>
          <year>2000</year>
          <volume>103</volume>
          <fpage>481</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)00139-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481&#x2013;90. <pub-id pub-id-type="pmid">11081634</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergers</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brekken</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vu</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Itoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tamaki</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis</article-title>
          <source>Nat Cell Biol</source>
          <year>2000</year>
          <volume>2</volume>
          <fpage>737</fpage>
          <lpage>744</lpage>
          <pub-id pub-id-type="doi">10.1038/35036374</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737&#x2013;44. <pub-id pub-id-type="pmid">11025665</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nielsen</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Sehested</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kjeldsen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Borregaard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rygaard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dan&#xF8;</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer</article-title>
          <source>Lab Invest</source>
          <year>1997</year>
          <volume>77</volume>
          <fpage>345</fpage>
          <lpage>355</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dan&#xF8; K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345&#x2013;55. <pub-id pub-id-type="pmid">9354769</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCawley</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Mudgett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Matrisian</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>A protective role for matrix metalloproteinase-3 in squamous cell carcinoma</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>6965</fpage>
          <lpage>6972</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0910</pub-id>
        </citation>
        <citation citation-type="display-unstructured">McCawley LJ, Crawford HC, King LE, Jr., Mudgett J, Matrisian LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004;64:6965&#x2013;72. <pub-id pub-id-type="pmid">15466188</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jost</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Folgueras</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Fr&#xE9;rart</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pendas</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Blacher</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Houard</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice</article-title>
          <source>Cancer Res</source>
          <year>2006</year>
          <volume>66</volume>
          <fpage>5234</fpage>
          <lpage>5241</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4315</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jost M, Folgueras AR, Fr&#xE9;rart F, Pendas AM, Blacher S, Houard X, et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res 2006;66:5234&#x2013;41. <pub-id pub-id-type="pmid">16707448</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fantozzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Christofori</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Mouse models of breast cancer metastasis</article-title>
          <source>Breast Cancer Res</source>
          <year>2006</year>
          <volume>8</volume>
          <fpage>212</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1186/bcr1530</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fantozzi A, Christofori G. Mouse models of breast cancer metastasis. Breast Cancer Res 2006;8:212&#x2013;22. <pub-id pub-id-type="pmid">16887003</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muraoka</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Roebuck</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Sanders</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Brantley-Sieders</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gorska</surname>
              <given-names>AE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor &#x3B2;1</article-title>
          <source>Mol Cell Biol</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>8691</fpage>
          <lpage>8703</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.23.23.8691-8703.2003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor &#x3B2;1. Mol Cell Biol 2003;23:8691&#x2013;703. <pub-id pub-id-type="pmid">14612410</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oshima</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Lesperance</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Munoz</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hebbard</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ranscht</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sharan</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiogenic acceleration of Neu induced mammary tumor progression and metastasis</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>169</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-1944</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Oshima RG, Lesperance J, Munoz V, Hebbard L, Ranscht B, Sharan N, et al. Angiogenic acceleration of Neu induced mammary tumor progression and metastasis. Cancer Res 2004;64:169&#x2013;79. <pub-id pub-id-type="pmid">14729621</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winding</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>NicAmhlaoibh</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Misander</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>H&#xF8;egh-Andersen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Andersen</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Holst-Hansen</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice</article-title>
          <source>Clin Cancer Res</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>1932</fpage>
          <lpage>1939</lpage>
        </citation>
        <citation citation-type="display-unstructured">Winding B, NicAmhlaoibh R, Misander H, H&#xF8;egh-Andersen P, Andersen TL, Holst-Hansen C, et al. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 2002;8:1932&#x2013;9. <pub-id pub-id-type="pmid">12060638</pub-id></citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoneda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hiraga</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Crosstalk between cancer cells and bone microenvironment in bone metastasis</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2005</year>
          <volume>328</volume>
          <fpage>679</fpage>
          <lpage>687</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbrc.2004.11.070</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005;328:679&#x2013;87. <pub-id pub-id-type="pmid">15694401</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Palumbo</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Potter</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Talmage</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Degen</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice</article-title>
          <source>Cancer Res</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>6966</fpage>
          <lpage>6972</lpage>
        </citation>
        <citation citation-type="display-unstructured">Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966&#x2013;72. <pub-id pub-id-type="pmid">12460914</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Palumbo</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Kombrinck</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Drew</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Grimes</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Kiser</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Degen</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells</article-title>
          <source>Blood</source>
          <year>2000</year>
          <volume>96</volume>
          <fpage>3302</fpage>
          <lpage>3309</lpage>
        </citation>
        <citation citation-type="display-unstructured">Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302&#x2013;9. <pub-id pub-id-type="pmid">11071621</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pecenka</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tsukamoto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Parslow</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Guzman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>TP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice</article-title>
          <source>Mol Cell Biol</source>
          <year>1992</year>
          <volume>12</volume>
          <fpage>147</fpage>
          <lpage>154</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kwan H, Pecenka V, Tsukamoto A, Parslow TG, Guzman R, Lin TP, et al. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 1992;12:147&#x2013;54. <pub-id pub-id-type="pmid">1530875</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takayama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>LaRochelle</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Sharp</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Otsuka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kriebel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Anver</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1997</year>
          <volume>94</volume>
          <fpage>701</fpage>
          <lpage>706</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.94.2.701</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701&#x2013;6. <pub-id pub-id-type="pmid">9012848</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deryugina</surname>
              <given-names>EI</given-names>
            </name>
            <name>
              <surname>Quigley</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Matrix metalloproteinases and tumor metastasis</article-title>
          <source>Cancer Metastasis Rev</source>
          <year>2006</year>
          <volume>25</volume>
          <fpage>9</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1007/s10555-006-7886-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9&#x2013;34. <pub-id pub-id-type="pmid">16680569</pub-id></citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houghton</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Grisolano</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Baumann</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Hautamaki</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Nehring</surname>
              <given-names>LC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases</article-title>
          <source>Cancer Res</source>
          <year>2006</year>
          <volume>66</volume>
          <fpage>6149</fpage>
          <lpage>6155</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0297</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 2006;66:6149&#x2013;55. <pub-id pub-id-type="pmid">16778188</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ling</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Jacovina</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Deora</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Febbraio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Simantov</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Silverstein</surname>
              <given-names>RL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>38</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200419684</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004;113:38&#x2013;48. <pub-id pub-id-type="pmid">14702107</pub-id></citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Razzaq</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Bass</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vines</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Werner</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Whawell</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4)</article-title>
          <source>J Biol Chem</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>42679</fpage>
          <lpage>42685</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M305695200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Razzaq TM, Bass R, Vines DJ, Werner F, Whawell SA, Ellis V. Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4). J Biol Chem 2003;278:42679&#x2013;85. <pub-id pub-id-type="pmid">12913003</pub-id></citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mizoguchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sasahara</surname>
              <given-names>RM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis</article-title>
          <source>Cell</source>
          <year>2001</year>
          <volume>107</volume>
          <fpage>789</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00597-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107:789&#x2013;800. <pub-id pub-id-type="pmid">11747814</pub-id></citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heppner</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Matrisian</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Rodgers</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response</article-title>
          <source>Am J Pathol</source>
          <year>1996</year>
          <volume>149</volume>
          <fpage>273</fpage>
          <lpage>282</lpage>
        </citation>
        <citation citation-type="display-unstructured">Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273&#x2013;82. <pub-id pub-id-type="pmid">8686751</pub-id></citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matrisian</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Cancer biology: extracellular proteinases in malignancy</article-title>
          <source>Curr Biol</source>
          <year>1999</year>
          <volume>9</volume>
          <fpage>R776</fpage>
          <lpage>R778</lpage>
          <pub-id pub-id-type="doi">10.1016/S0960-9822(00)80011-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Matrisian LM. Cancer biology: extracellular proteinases in malignancy. Curr Biol 1999;9:R776&#x2013;8. <pub-id pub-id-type="pmid">10531025</pub-id></citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hulboy</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Gautam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fingleton</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Matrisian</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse</article-title>
          <source>Oncol Rep</source>
          <year>2004</year>
          <volume>12</volume>
          <fpage>13</fpage>
          <lpage>17</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hulboy DL, Gautam S, Fingleton B, Matrisian LM. The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. Oncol Rep 2004;12:13&#x2013;7. <pub-id pub-id-type="pmid">15201952</pub-id></citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sacco</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Soldati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Indraccolo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cato</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Cattaneo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scanziani</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer</article-title>
          <source>Gene Ther</source>
          <year>2003</year>
          <volume>10</volume>
          <fpage>1903</fpage>
          <lpage>1909</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.gt.3302082</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sacco MG, Soldati S, Indraccolo S, Cato EM, Cattaneo L, Scanziani E, et al. Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther 2003;10:1903&#x2013;9. <pub-id pub-id-type="pmid">14502219</pub-id></citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CIS</term>
          <def>
            <p>carcinoma in situ</p>
          </def>
        </def-item>
        <def-item>
          <term>DCIS</term>
          <def>
            <p>ductal CIS</p>
          </def>
        </def-item>
        <def-item>
          <term>DMBA</term>
          <def>
            <p>7,12-dimethylbenzanthracene</p>
          </def>
        </def-item>
        <def-item>
          <term>ECM</term>
          <def>
            <p>extracellular matrix</p>
          </def>
        </def-item>
        <def-item>
          <term>MMP</term>
          <def>
            <p>matrix metalloprotease</p>
          </def>
        </def-item>
        <def-item>
          <term>MMTV</term>
          <def>
            <p>mouse mammary tumor virus long terminal repeat promoter</p>
          </def>
        </def-item>
        <def-item>
          <term>PA system</term>
          <def>
            <p>plasminogen activation system</p>
          </def>
        </def-item>
        <def-item>
          <term>PAI-1</term>
          <def>
            <p>plasminogen activator inhibitor-1</p>
          </def>
        </def-item>
        <def-item>
          <term>pKal</term>
          <def>
            <p>plasma kallikrein</p>
          </def>
        </def-item>
        <def-item>
          <term>Plg</term>
          <def>
            <p>plasminogen</p>
          </def>
        </def-item>
        <def-item>
          <term>PymT</term>
          <def>
            <p>polyomavirus middle T antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>SV40-T</term>
          <def>
            <p>simian virus 40 large T antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>TDLU</term>
          <def>
            <p>terminal ductal lobular unit</p>
          </def>
        </def-item>
        <def-item>
          <term>TGF-&#x3B2;</term>
          <def>
            <p>transforming growth factor-&#x3B2;</p>
          </def>
        </def-item>
        <def-item>
          <term>TIMP</term>
          <def>
            <p>tissue inhibitor of metalloproteases</p>
          </def>
        </def-item>
        <def-item>
          <term>tPA</term>
          <def>
            <p>tissue plasminogen activator</p>
          </def>
        </def-item>
        <def-item>
          <term>uPA</term>
          <def>
            <p>urokinase plasminogen activator</p>
          </def>
        </def-item>
        <def-item>
          <term>uPAR</term>
          <def>
            <p>urokinase receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>VEGF</term>
          <def>
            <p>vascular endothelial growth factor</p>
          </def>
        </def-item>
        <def-item>
          <term>WAP</term>
          <def>
            <p>whey acidic protein promoter</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>
</pmc-articleset>